Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.
about
Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in ChildrenClinical determinants of calcineurin inhibitor disposition: a mechanistic review.Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients.
P2860
Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Engraftment syndrome, but not ...... n pediatric hematopoietic SCT.
@en
type
label
Engraftment syndrome, but not ...... n pediatric hematopoietic SCT.
@en
prefLabel
Engraftment syndrome, but not ...... n pediatric hematopoietic SCT.
@en
P2093
P2860
P356
P1476
Engraftment syndrome, but not ...... n pediatric hematopoietic SCT.
@en
P2093
K Sakashita
M Shiohara
R Yanagisawa
T Shigemura
Y Katsuyama
Y Nakazawa
P2860
P2888
P356
10.1038/BMT.2010.64
P407
P577
2010-04-12T00:00:00Z
P5875
P6179
1001969954